An update on tinea capitis in children
Pediatric Dermatology · 2024-11 · 41 (6) · 1030-1039
DOI: 10.1111/pde.15708 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pediatric Dermatology, online erschienen am 07.08.2024. Verfasst von Aditya K Gupta und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, Department of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Antifungal Agents, Tinea Capitis. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Tinea capitis presents a significant public health care challenge due to its contagious nature, and potential long‐term consequences if unrecognized and untreated. This review explores the prevalence, risk factors, diagnostic methods, prevention strategies, impact on quality of life, and treatment options for pediatric tinea capitis. Epidemiological analysis spanning from 1990 to 1993 and 2020 to 2023 reveals prevalence patterns of pediatric tinea capitis influenced by geographic, demographic, and environmental factors. Notably, Trichophyton species is most prevalent in North America; however, Microsporum species remain the primary causative agent globally, with regional variations. Risk factors include close contact and environmental conditions, emphasizing the importance of preventive measures. Accurate diagnosis relies on clinical evaluation, microscopic examination, and fungal culture. Various treatment modalities including systemic antifungals show efficacy, with terbinafine demonstrating superior mycological cure rates particularly for Trichophyton species. Recurrent infections and the potential development of resistance can pose challenges. Therefore, confirming the diagnosis, appropriately educating the patient/caregiver, accurate drug and dose utilization, and compliance are important components of clinical cure. Untreated or poorly treated tinea capitis can lead to chronic infection, social stigma, and psychological distress in affected children. Prevention strategies focus on early detection and healthy lifestyle habits. Collaborative efforts between healthcare providers and public health agencies are important in treating pediatric tinea capitis and improving patient outcomes. Education and awareness initiatives play a vital role in prevention and community‐level intervention to minimize spread of infection. Future research should explore diagnostic advances, novel treatments, and resistance mechanisms in order to mitigate the disease burden effectively.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Dermatology, Department of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada.
- Research and Medical Writing, Mediprobe Research Inc., London, Ontario, Canada.
- Department of Urban Health and Population Science, Center for Urban Bioethics, Lewis Katz School of Medicine, Philadelphia, Pennsylvania, USA.
- Department of Dermatology, University of California, San Diego School of Medicine, San Diego, California, USA.
- Department of Dermatology, Scripps Clinic, San Diego, California, USA.
Zitieren
APA
Gupta, A. K., Polla Ravi, S., Wang, T., Faour, S., Bamimore, M. A., Heath, C. R., & Friedlander, S. F. (2024). An update on tinea capitis in children. Pediatric Dermatology, 41(6), 1030-1039. https://doi.org/10.1111/pde.15708
Vancouver
Gupta AK, Polla Ravi S, Wang T, Faour S, Bamimore MA, Heath CR, et al. An update on tinea capitis in children. Pediatric Dermatology. 2024;41(6):1030-1039. doi:10.1111/pde.15708
BibTeX
@article{Gupta2024,
author = {Gupta, Aditya K and Polla Ravi, Shruthi and Wang, Tong and Faour, Sara and Bamimore, Mary A and Heath, Candrice R and Friedlander, Sheila Fallon},
title = {An update on tinea capitis in children},
journal = {Pediatric Dermatology},
year = {2024},
volume = {41},
number = {6},
pages = {1030--1039},
doi = {10.1111/pde.15708}
}
EUVIMED